Aurobindo Pharma Limited

NSEI:AUROPHARMA Stock Report

Market Cap: ₹721.2b

Aurobindo Pharma Dividends and Buybacks

Dividend criteria checks 3/6

Aurobindo Pharma is a dividend paying company with a current yield of 0.24% that is well covered by earnings.

Key information

0.2%

Dividend yield

1.3%

Buyback Yield

Total Shareholder Yield1.5%
Future Dividend Yield0.4%
Dividend Growth4.8%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per share₹3.000
Payout ratio2%

Recent dividend and buyback updates

Recent updates

Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Dec 18
Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?

Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Nov 12
Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts

Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Oct 20
Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price

Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

Sep 10
Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)

This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Aug 23
This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet

Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Aug 13
Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422

Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Jun 20
Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly

Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

May 29
Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

May 22
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value

Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Apr 10
Aurobindo Pharma Limited's (NSE:AUROPHARMA) Earnings Are Not Doing Enough For Some Investors

Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Jan 14
Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Worth ₹1.1k Based On Its Intrinsic Value?

Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Dec 27
Aurobindo Pharma (NSE:AUROPHARMA) Has A Pretty Healthy Balance Sheet

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: AUROPHARMA's dividend payments have been volatile in the past 10 years.

Growing Dividend: AUROPHARMA's dividend payments have increased over the past 10 years.


Dividend Yield vs Market

Aurobindo Pharma Dividend Yield vs Market
How does AUROPHARMA dividend yield compare to the market?
SegmentDividend Yield
Company (AUROPHARMA)0.2%
Market Bottom 25% (IN)0.2%
Market Top 25% (IN)1.1%
Industry Average (Pharmaceuticals)0.7%
Analyst forecast (AUROPHARMA) (up to 3 years)0.4%

Notable Dividend: AUROPHARMA's dividend (0.24%) is higher than the bottom 25% of dividend payers in the Indian market (0.24%).

High Dividend: AUROPHARMA's dividend (0.24%) is low compared to the top 25% of dividend payers in the Indian market (1.1%).


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (2.4%), AUROPHARMA's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: AUROPHARMA is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 04:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurobindo Pharma Limited is covered by 54 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Meeta ShettyAsian Markets Securities Private Limited
Kamlesh KotakAsian Markets Securities Private Limited
Harith AhamedAvendus Spark